Preventive Screening & Blood Biomarkers • ICD-10-CM R60.1
Massive edema (anasarca)
Also known as: Anasarca
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM R60.1 • 6 Linked .gov / PubMed Citations
•
Governance: Dr. Devon Caldwell, DO, MPH (NPI #1568063758)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
Massive edema (anasarca) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Massive edema (anasarca) (also termed Anasarca) is an ICD-10-CM indexed diagnosis (R60.1) within Preventive Screening & Blood Biomarkers.
- 2 Real-world patient consensus: Synonyms for Massive edema (anasarca) (R60.1): Anasarca (Preventive & Labs).
- 3 Typical cash cost range: Clinicians assessing Massive edema (anasarca) focus on systemic inflammation [Massive edema (anasarca) R60.1] and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Massive edema (anasarca): maintaining CBC, CMP & in Massive edema (anasarca) (R60.1: eGFR Baseline) within Within optimal preventive reference intervals (R60.1).
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about Massive edema (anasarca)
What Is Massive edema (anasarca)?
Massive edema (anasarca) (also termed Anasarca) is an ICD-10-CM indexed diagnosis (R60.1) within Preventive Screening & Blood Biomarkers. Clinical evaluation centers on USPSTF age/sex-appropriate preventive in Massive edema (anasarca) (R60.1: screenings) alongside serial CBC, CMP & in Massive edema (anasarca) (R60.1: eGFR Baseline) tracking (Within optimal preventive reference intervals (R60.1)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Massive edema (anasarca) (R60.1) features systemic inflammation [Massive edema (anasarca) R60.1]. therapeutic stabilization in preventive & labs is verified against 25-Hydroxy Vitamin D, in Massive edema (anasarca) (R60.1: Ferritin & B12).
Common Symptoms & Clinical Signs
- • Presentation of Massive edema (anasarca) (R60.1): proactive annual or in Massive edema (anasarca) (R60.1: semiannual health checkup)
- • Secondary Massive edema (anasarca) clinical sign: follow-up of borderline in Massive edema (anasarca) (R60.1: laboratory values before)
- • Symptom flares in Massive edema (anasarca) correlating with CBC, CMP & in Massive edema (anasarca) (R60.1: eGFR Baseline) deviation outside Within optimal preventive reference intervals (R60.1)
- • Functional preventive & labs impact requiring USPSTF age/sex-appropriate preventive in Massive edema (anasarca) (R60.1: screenings) evaluation (R60.1)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Massive edema (anasarca) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | R60.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Preventive Screening & Blood Biomarkers | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: CBC, CMP & in Massive edema (anasarca) (R60.1: eGFR Baseline) | Within optimal preventive reference intervals (R60.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D, in Massive edema (anasarca) (R60.1: Ferritin & B12) | 25(OH)D 40–65 ng/mL; Ferritin 50–150 ng/mL (R60.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ApoB, HbA1c & in Massive edema (anasarca) (R60.1: hs-CRP Triad) | ApoB < 80 mg/dL; HbA1c < 5.5%; hs-CRP < 1.0 mg/L (R60.1) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for Massive edema (anasarca)
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Bumetanide Bumex, Enbumyst • RxCUI 197419 | Loop Diuretic | 89% | $0.1250 | $ 6.39 /mo |
| Furosemide Lasix, Lasix Onyu • RxCUI 310429 | Loop Diuretic | 91% | $0.2231 | $ 5.58 /mo |
| Triamterene Dyrenium • RxCUI 198312 | Potassium-sparing Diuretic | 77% | $5.8627 | $ 151.63 /mo |
| Acetazolamide Diamox • RxCUI 197303 | Carbonic Anhydrase Inhibitor | 89% | $0.0935 | $ 6.66 /mo |
| Torsemide Soaanz, Demadex • RxCUI 198371 | Loop Diuretic | 92% | $0.0552 | $ 5.74 /mo |
| Triamterene and Hydrochlorothiazide Triamterene and Hydrochlorothiazide Generic • RxCUI 310812 | Potassium-sparing Diuretic | 74% | $0.0930 | $ 12.27 /mo |
| Chlorothiazide Diuril • RxCUI 213439 | Thiazide Diuretic | 84% | $1.8100 | $ 81.81 /mo |
| Bupropion Hydrochloride SR Wellbutrin SR • RxCUI 993503 | Aminoketone | 94% | $0.1195 | $ 5.83 /mo |
| Lasix (Furosemide) Lasix • RxCUI 197732 | Loop Diuretic | 81% | $1.0461 | $ 5.58 /mo |
| Ethacrynic Acid Edecrin • RxCUI 617325 | Loop Diuretic | 82% | $0.7573 | $ 17.77 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Massive edema (anasarca))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Long-Term safety and real-world benefits of Xanomeline and Trospium Chloride in: What a 366-Participant Study Found Long-term treatment with X/T over 52 weeks was safe, generally well tolerated, and associated with durable symptom improvement in people with schizophrenia. The American journal of psychiatry • 2026-03-01 • Phase III Randomized Trial | N = 366 | 93/100 | PMID 41634905 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone CAFS at week 48 indicated Once Daily dosing did not show a statistically significant difference vs. Muscle & nerve • 2025-09-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40474686 ↗ |
| Can This Approach Help? Inside the Latest Research on Patterns, predictors and prognostic relevance of high-grade hematotoxicity after Older age and female sex are associated with higher incidence of HAE. Journal of neuro-oncology • 2023-01-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 36609807 ↗ |
Zero-PHI Patient Support & Cohort Discussions
Massive edema (anasarca) Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter Massive edema (anasarca) community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Massive edema (anasarca).